

REMARKS

Claims 1-11 are active in the present application. The claims are amended to remove multiple dependencies. Support for Claim 10 and 11 is found in Claim 8 and the specification as filed. No new matter is added. An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
NFO/DJP/smi

I:\user\DJPER\204415US-pr.wpd

WILLIAM E. BEAUMONT
REGISTRATION NUMBER 30,996

204415US0PCT

Marked-Up Copy

Serial No: _____

Amendment Filed on: _____

IN THE CLAIMS

Please amend the claims as follows:

--8. (Amended) The immunosuppressant used in claim 1 [Claims 1 to 7] is tacrolimus, cyclosporin A or 33-epi-chloro-33-desoxyascomycin.--